CO2024015229A2 - Compuestos y usos de estos - Google Patents
Compuestos y usos de estosInfo
- Publication number
- CO2024015229A2 CO2024015229A2 CONC2024/0015229A CO2024015229A CO2024015229A2 CO 2024015229 A2 CO2024015229 A2 CO 2024015229A2 CO 2024015229 A CO2024015229 A CO 2024015229A CO 2024015229 A2 CO2024015229 A2 CO 2024015229A2
- Authority
- CO
- Colombia
- Prior art keywords
- formula
- compounds
- cancer
- present disclosure
- pharmaceutically acceptable
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340927P | 2022-05-11 | 2022-05-11 | |
| PCT/US2023/021793 WO2023220219A1 (en) | 2022-05-11 | 2023-05-11 | Compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024015229A2 true CO2024015229A2 (es) | 2025-03-06 |
Family
ID=86732694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0015229A CO2024015229A2 (es) | 2022-05-11 | 2024-11-07 | Compuestos y usos de estos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12139487B2 (enExample) |
| EP (1) | EP4522280A1 (enExample) |
| JP (2) | JP7531656B2 (enExample) |
| KR (1) | KR20250024923A (enExample) |
| CN (1) | CN119677738A (enExample) |
| AR (1) | AR129299A1 (enExample) |
| AU (1) | AU2023270055A1 (enExample) |
| CA (1) | CA3252955A1 (enExample) |
| CL (1) | CL2024003450A1 (enExample) |
| CO (1) | CO2024015229A2 (enExample) |
| DO (1) | DOP2024000231A (enExample) |
| IL (1) | IL316531A (enExample) |
| MX (1) | MX2024013838A (enExample) |
| PE (1) | PE20250261A1 (enExample) |
| TW (2) | TWI864749B (enExample) |
| WO (1) | WO2023220219A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025008060A1 (en) * | 2023-07-05 | 2025-01-09 | Janssen Pharmaceutica Nv | 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers |
| WO2025099307A1 (en) * | 2023-11-10 | 2025-05-15 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of diseases |
| WO2025237242A1 (zh) * | 2024-05-14 | 2025-11-20 | 上海和誉生物医药科技有限公司 | 一种smarca2抑制剂及其应用 |
| CN118908980B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种多环化合物 |
| CN118930537B (zh) * | 2024-07-23 | 2025-05-13 | 上海信诺维生物医药有限公司 | 一种抑制brm的化合物 |
| CN118930561B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种稠环化合物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101402474B1 (ko) | 2006-04-26 | 2014-06-19 | 제넨테크, 인크. | 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물 |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| AU2015295405B2 (en) | 2014-08-01 | 2020-04-09 | Nuevolution A/S | Compounds active towards bromodomains |
| PH12022551937A1 (en) * | 2020-01-29 | 2023-10-23 | Foghorn Therapeutics Inc | Compounds and uses thereof |
| KR20220146479A (ko) * | 2020-01-29 | 2022-11-01 | 포그혼 쎄라퓨틱스 인크. | 화합물 및 그의 용도 |
| JP2023512038A (ja) * | 2020-01-29 | 2023-03-23 | フォグホーン セラピューティクス インコーポレイテッド | 化合物及びその使用 |
| IL295177A (en) * | 2020-01-29 | 2022-09-01 | Foghorn Therapeutics Inc | compounds and their uses |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| MX2023005436A (es) | 2020-11-10 | 2023-07-25 | Foghorn Therapeutics Inc | Compuestos y usos de estos. |
-
2023
- 2023-05-11 IL IL316531A patent/IL316531A/en unknown
- 2023-05-11 AU AU2023270055A patent/AU2023270055A1/en active Pending
- 2023-05-11 EP EP23729898.9A patent/EP4522280A1/en active Pending
- 2023-05-11 PE PE2024002469A patent/PE20250261A1/es unknown
- 2023-05-11 AR ARP230101168A patent/AR129299A1/es unknown
- 2023-05-11 US US18/315,526 patent/US12139487B2/en active Active
- 2023-05-11 WO PCT/US2023/021793 patent/WO2023220219A1/en not_active Ceased
- 2023-05-11 JP JP2023078608A patent/JP7531656B2/ja active Active
- 2023-05-11 KR KR1020247041093A patent/KR20250024923A/ko active Pending
- 2023-05-11 CN CN202380053231.6A patent/CN119677738A/zh active Pending
- 2023-05-11 TW TW112117604A patent/TWI864749B/zh active
- 2023-05-11 CA CA3252955A patent/CA3252955A1/en active Pending
- 2023-05-11 TW TW113141340A patent/TW202506693A/zh unknown
-
2024
- 2024-07-30 JP JP2024122975A patent/JP2024156779A/ja active Pending
- 2024-10-25 US US18/926,578 patent/US20250066354A1/en active Pending
- 2024-11-07 CO CONC2024/0015229A patent/CO2024015229A2/es unknown
- 2024-11-08 MX MX2024013838A patent/MX2024013838A/es unknown
- 2024-11-11 DO DO2024000231A patent/DOP2024000231A/es unknown
- 2024-11-11 CL CL2024003450A patent/CL2024003450A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US12139487B2 (en) | 2024-11-12 |
| US20250066354A1 (en) | 2025-02-27 |
| JP7531656B2 (ja) | 2024-08-09 |
| TWI864749B (zh) | 2024-12-01 |
| PE20250261A1 (es) | 2025-01-29 |
| CA3252955A1 (en) | 2023-11-16 |
| DOP2024000231A (es) | 2024-12-15 |
| JP2024156779A (ja) | 2024-11-06 |
| AU2023270055A1 (en) | 2024-11-28 |
| EP4522280A1 (en) | 2025-03-19 |
| AR129299A1 (es) | 2024-08-07 |
| US20230365560A1 (en) | 2023-11-16 |
| TW202411228A (zh) | 2024-03-16 |
| IL316531A (en) | 2024-12-01 |
| TW202506693A (zh) | 2025-02-16 |
| KR20250024923A (ko) | 2025-02-20 |
| WO2023220219A1 (en) | 2023-11-16 |
| CL2024003450A1 (es) | 2025-03-14 |
| MX2024013838A (es) | 2025-03-07 |
| CN119677738A (zh) | 2025-03-21 |
| JP2023168298A (ja) | 2023-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024003450A1 (es) | Compuestos y usos de estos | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2022010547A2 (es) | Compuestos y usos de los mismos | |
| ECSP24009853A (es) | Compuestos tricíclicos como inhibidores de kras | |
| CL2020002511A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| CL2020002198A1 (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| CL2022000457A1 (es) | Triazolopirimidinas como inhibidores de a2a/a2b. | |
| ECSP23070418A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| CU20190080A7 (es) | Derivados de isoindolina útiles para tratar la esteatohepatitis no alcohólica y otras enfermedades de curación disfuncional del tejido y fibrosis | |
| MX2022001158A (es) | Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales. | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| DOP2023000223A (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| ECSP19066134A (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CO2018007436A2 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| CO2025003099A2 (es) | Compuestos para el tratamiento del cáncer | |
| MX2024013840A (es) | Derivados de pirazina y usos de los mismos | |
| MX2024013841A (es) | Derivados de pirazina y usos de estos | |
| ECSP22093652A (es) | Compuestos de imidazopiridazina y usos de los mismos | |
| AR126389A1 (es) | Compuestos tricíclicos como inhibidores de kras | |
| AR117459A1 (es) | Imidazopiridina y compuestos de imidazopiridazina y usos de los mismos | |
| MX2022001023A (es) | Compuestos de aminotiolester y usos de los mismos. |